GlaxoSmithKline (LON:GSK)‘s stock had its “hold” rating reissued by analysts at Kepler Capital Markets in a report released on Thursday, November 22nd.
Several other analysts have also recently commented on the company. Credit Suisse Group restated a “neutral” rating on shares of GlaxoSmithKline in a report on Monday, November 12th. Liberum Capital restated a “hold” rating and issued a GBX 1,700 ($22.21) price target on shares of GlaxoSmithKline in a report on Monday, November 5th. Barclays restated an “overweight” rating on shares of GlaxoSmithKline in a report on Friday, November 2nd. Cfra set a GBX 1,650 ($21.56) price target on GlaxoSmithKline and gave the company a “neutral” rating in a report on Thursday, November 1st. Finally, UBS Group restated a “buy” rating and issued a GBX 1,700 ($22.21) price target on shares of GlaxoSmithKline in a report on Thursday, November 1st. One research analyst has rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of GBX 1,512.99 ($19.77).
GSK opened at GBX 1,437.40 ($18.78) on Thursday. GlaxoSmithKline has a 12 month low of GBX 1,235.20 ($16.14) and a 12 month high of GBX 1,724.50 ($22.53).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Story: What is the float in trading stocks?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.